Virus cocktail takes on tough liver tumors

NCT ID NCT07381309

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether injecting an oncolytic virus (H101) directly into liver tumors, along with radiation, chemotherapy, targeted therapy, and immunotherapy, can shrink or control colorectal cancer that has spread to the liver and cannot be removed by surgery. The study will enroll 114 adults with a specific type of colorectal cancer (MSS/pMMR). The goal is to see if this powerful combination improves response rates and helps patients live longer without their cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oncolytic virus H101
What this could lead to
If successful, this combination approach could offer a new treatment option for people with hard-to-treat colorectal cancer that has spread to the liver.
What could go wrong
This is an early phase 2 trial with only 114 participants, so results may not apply to everyone. Combining multiple therapies also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.